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Reppe S, Stilgren L, Abrahamsen B, Olstad OK, Cero F,
Brixen K, Nissen-Meyer LS, Gautvik KM. Abnormal muscle and
hematopoietic gene expression may be important for clinical mor-
bidity in primary hyperparathyroidism. Am J Physiol Endocrinol
Metab 292: E1465–E1473, 2007. First published January 16, 2007;
doi:10.1152/ajpendo.00487.2006.—In primary hyperparathyroidism
(PHPT), excess PTH secretion by adenomatous or hyperplastic para-
thyroid glands leads to elevated serum [Ca2]. Patients present
complex symptoms of muscular fatigue, various neuropsychiatric,
neuromuscular, and cardiovascular manifestations, and, in advanced
disease, kidney stones and metabolic bone disease. Our objective was
to characterize changes in muscle and hematopoietic gene expression
in patients with reversible mild PHPT after parathyroidectomy and
possibly link molecular pathology to symptoms. Global mRNA pro-
filing using Affymetrix gene chips was carried out in biopsies ob-
tained before and 1 yr after parathyroidectomy in seven patients
discovered by routine blood [Ca2] screening. The tissue distribution
of PTH receptor (PTHR1 and PTHR2) mRNAs were quantitated
using real-time RT-PCR in unrelated persons to define PTH target
tissues. Of about 10,000 expressed genes, 175 muscle, 169 hemato-
logical, and 99 bone-associated mRNAs were affected. Notably, the
major part of muscle-related mRNAs was increased whereas hema-
tological mRNAs were predominantly decreased during disease.
Functional and molecular network analysis demonstrated major alter-
ations of several tissue characteristic groups of mRNAs as well as
those belonging to common cell signaling and major metabolic
pathways. PTHR1 and PTHR2 mRNAs were more abundantly ex-
pressed in muscle and brain than in hematopoietic cells. We suggest
that sustained stimulation of PTH receptors present in brain, muscle,
and hematopoietic cells have to be considered as one independent,
important cause of molecular disease in PHPT leading to profound
alterations in gene expression that may help explain symptoms like
muscle fatigue, cardiovascular pathology, and precipitation of psychi-
atric illness.
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THE PREVALENCE OF PRIMARY HYPERPARATHYROIDISM (PHPT) var-
ies by age and sex, affecting 1 in 500 females and 1 in 2,000
males over the age of 40 yr (7), or1% of the adult population
(19). The prevalence of PHPT increases with age in both males
and females. PHPT is usually due to benign tumors or hyper-
plasia affecting one or several parathyroid glands, which there-
fore secrete constitutively too much parathyroid hormone
(PTH), leading to increased levels of blood calcium. Loss of
calcium from the skeleton leads to osteoporosis (OP) and
osteomalacia (26). There is a growing recognition that symp-
toms rising early from organ systems other than bone and
kidneys are important and add to the morbidity of patients with
PHPT in addition to the more classical findings of nephroli-
thiasis and osteopenia (48). Many reports (14, 23, 24, 42, 43)
emphasize the change in the clinical presenting picture from
renal, bone-related, and gastrointestinal manifestations to psy-
chological and psychiatric disorders as well as feelings of
muscular weakness, apathy, and ill-defined mental symptoms.
An increased cardiovascular morbidity has been reported even
in mild disease (2), leading to overpresentation of cardiac death
in patients with symptomatic PHPT both before and after
parathyroidectomy (PTX), suggesting development of nonre-
versible changes. The actions of PTH are mediated through three
types of receptors: PTH/PTH-related peptide receptor (PTHR1),
the NH2-terminal PTH receptor II (PTHR2), and the COOH-
terminal PTH receptor (C-PTHR) (22, 38, 46, 47). In humans,
PTHR1 mRNA is reported to be widely expressed in tissues like
brain, striated muscle, heart muscle, kidney, and liver (38, 46).
The PTHR2 mRNA shows a more restricted distribution and has
lower affinity for PTH compared with PTHR1, but it is present in
blood cells (39) and abundant in the brain and pancreas (47). The
COOH-terminal part of PTH is essential for binding to the
C-PTHR receptor, which has not yet been cloned but is highly
expressed, e.g., in rat osteocytes (10).
Very little is known about the molecular pathology associ-
ated with a chronic excessive action exerted by PTH in differ-
ent target tissues in patients with PHPT. The aim of the present
study was to describe in detail changes in gene expression in
biopsies from patients with well-defined and characterized
early PHPT before and after surgery when normalization of
bone and biochemical markers had occurred. We used each
patient as his/her own control to describe the molecular pa-
thology expressed as mRNA profiles and suggest that the
results may have clinical consequences reflecting chronic PTH
receptor stimulation.
METHODS
Patients and biopsies. Seven arbitrarily chosen patients from 53 to
75 yr of age (mean 60.3 yr), without signs of organ affection but with
clinical biochemical evidence of mild PHPT, were included. Bio-
chemical blood diagnostic and bone parameters for the patients have
been described previously (35). Briefly, PTH, ionized calcium, and
1,25(OH)2D, as well as bone formation and resorption markers, and
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were all significantly reduced 1 yr after surgery, whereas bone mineral
density levels in spine and hip increased significantly. The diagnosis
was established by elevated plasma PTH and ionized calcium, taking
care to rule out accessory conditions known to affect the PTH/calcium
balance. The patients were screened for interfering conditions such as
cardiovascular and renal disorders, endocrine disorders, and other
bone pathology. Vitamin D status [25(OH)D and 1,25(OH)2D] was
evaluated before inclusion. The patients had normal serum creatinine
levels. Following inclusion in this study, the patients underwent
successful PTX.
Biopsies containing bone, bone marrow, and remnants of skeletal
muscle tissue were taken from opposite but symmetrical places of os
ileum to avoid woven bone from the first biopsy before and 1 yr after
surgery. Biopsies were immediately frozen in liquid nitrogen and
stored at 70°C for RNA extraction.
The distribution of PTHR1 and PTHR2 in normal tissues and blood
cells, was studied in biopsies/blood samples obtained from other
patients taken during surgery. The receptors in central nervous system
(CNS) were analyzed in post mortem tissue from nondemented
humans (obtained from Netherlands Brain Bank, Amsterdam, The
Netherlands). The study was performed according to Title 45, US
Code of Federal Regulations, Part 46, “Protection of Human Sub-
jects,” and to the declaration of Helsinki II and approved by the Local
Ethics Committee (Ethics ref no. 19980012). Informed written con-
sent was obtained from each PHPT participant and other healthy
persons before entry. Also the examination of post mortem specimens
fulfilled all formal requirements.
Purification of RNA. RNA from biopsies and autopsies was purified
with the aid of TRIzol (Life Technologies, Gaithersburg, MD) and
RNeasy (Qiagen), as described (35). Isolation of lymphocytes and
monocytes was performed as described (31), and RNA from the
purified cell fractions was isolated with the aid of TRIzol. The RNA
quality was controlled by gel electrophoreses.
Microarray analysis. Double-stranded cDNA and biotin-labeled
cRNA probes were made from 5 g of total RNA by use of the
Superscript Choice system (Invitrogen) and the Enzo Bioarray, re-
spectively, according to recommendations from Affymetrix. This
cRNA was hybridized to HG-133A chips (Affymetrix) followed by
washing and staining on the GeneChips Fluidics Station 450
(Affymetrix). The chips were scanned on the Affymetrix GeneArray
2500 scanner. The quality of the RNA and probe was controlled by an
Affymetrix-based test measuring the ratio between 5 and 3 mRNAs
for -actin and GAPDH and found to be highly satisfactory. The
datasets originating from the 14 bone biopsies were processed by the
Affymetrix Mas 5.0 software according to manufacturer’s instruc-
tions.
The patients were coded, and all analyses were carried out blindly.
The samples from each patient were analyzed using the same kit for
cRNA probe synthesis and hybridized to chips from the same batch.
Intrabatch chip variation was found to be negligible. One patient,
patient 7, showed different overall mRNA profiles for genes related to
muscle, hematological, and bone matrix and was analyzed on two
chips from different batches to rule out technical causes. In general,
the differences in expression levels before/after operation were less
for patient 7. Of the 175 mRNAs related to muscle, 123 were on
average more than twofold changed in patients 1–6 compared with
only 24 in patient 7. Of the 169 mRNAs related to hematopoiesis, 46
were on average more than twofold changed in patients 1–6 compared
with only 15 in patient 7. Furthermore, 96 and 80% of muscle- and
hematopoiesis-related mRNAs increased or decreased, respectively,
on average in patients 1–6, whereas the corresponding numbers in
patient 7 were 14 and 44%, respectively.
Filtering and statistical analysis of Affymetrix data. First, the genes
were sorted by criteria based on uniformity of expression among
patients 1–6. Second, the average acceptable signal level before or
after PTX was set to be above 50 to include the probe set. Third, for
inclusion in the statistical analysis, changes reflecting a mean increase
or decrease of at least 40% (representing a log2 value of more than 0.5
or less than 0.5) were required. Patient 7 was treated as a special
case because she was considered to represent a different entity (see
RESULTS). Two statistical criteria were employed. For criterion 1, the
ratio of mRNA values between “sick” and “cured” for each probe set
(transcript) was given a P value by the Affymetrix Mas 5.0 program.
The median P value for one transcript from six patients was required
to be 0.05 or better according to the 0-hypothesis. For criterion 2, the
ratio of mRNA values between “sick” and “cured” were given a
P value by the Affymetrix Mas 5.0 program for each gene, and values
were then used in the empirical Bayes method for evaluation of the
significance of regulation (33, 41, 49).
Data evaluation using the Ingenuity Pathways Analysis program.
The canonical pathways that were identified using the Ingenuity
Pathways Analysis (IPA) program were evaluated employing the
right-tailed Fisher’s exact test to calculate levels of significance. The
P value for each pathway was calculated by comparing the number of
user-specified genes of interest (i.e., the regulated genes) that partic-
ipated in a given function or pathway relative to the total number of
occurrences of these genes in all functional/pathway annotations
stored in the Ingenuity Pathways knowledge base. Only annotations
that have more functions/canonical pathways analysis genes than
expected by chance (“right-tailed” annotations) were used. Although
the number of genes associated with a given function/pathway is an
important measure when calculating the P value in global analyses,
the P value is not simply proportional to this number but takes into
account how much information for these genes can be found in the
Ingenuity functional/pathway annotations. The probe sets of the Af-
fymetrix chips that were used covered more than 80% of the genes in
106 of 136 metabolic pathways covered by Ingenuity.
Real-time RT-PCR analysis. cDNA was synthesized from the same
RNA as was used for Affymetrix analysis using the High Capacity
cDNA Archive Kit (Applied Biosystems, Stockholm, Sweden) ac-
cording to the manufacturer’s specifications. Real-time RT-PCR was
performed using the ABI PRISM 7900HT Sequence Detection Sys-
tem and the 7900HT Micro Fluidic Card containing eight ports (PE
Applied Biosystems), using probes labeled with the fluorescent dye
FAM. TATA-binding protein (TBP) mRNA was included in the
reactions and used as internal standard since the variation between
signal values in each patient pre- and postsurgery was found to be
small [average 2.8% (SD 16.4%)]. Predesigned primers and a probe
labeled with the reporter fluorescent dye VIC, specific for TBP, were
used. The cDNA was amplified under the following conditions: 50°C
for 2 min, 94.5°C for 10 min, followed by cycles at 97°C for 30 s and
59.7°C for 1 min. The relative amount of mRNA for each gene was
calculated using the comparative CT method “Separate Tubes” ac-
cording to manufacturer’s instructions and adjusted and calculated
relative to the expression of TBP mRNA.
The genes and assay IDs selected for analysis are included in Fig.
4, A and B. The distributions of PTHR1 and PTHR2 were analyzed by
real-time RT-PCR employing the LightCycler and the Fast Start
Master SYBR Green kit (cat. no. 2239264, Roche Diagnostics)
according to the manufacturer’s instructions. One sample from each
organ/region from three different persons was analyzed in triplicate.
Cycling profile was 94°C for 5 min, then 40 cycles of 60°C for 30 s,
72°C for 30 s, and 95°C for 30 s, and 3 min at 72°C. Gene expression
was normalized to -actin. Primers were as follows: -actin, forward
GCTACAGCTTCACCACCACA, reverse GCCATCTCTTGCTC-
GAAGTC; PTHR1, forward GTCCCTGAGACCTCGGTGTA, re-
verse AGTACCGGAAGGTGCTCAAA; PTHR2, forward ATAGT-
GGGAGGCAGGGAGAT, reverse TTGGCATCCTTCAGTGTCTG.
RESULTS
Individual mRNA expression profiles in patients with PHPT
before and after PTX. The mRNA levels were analyzed in
biopsies from seven patients by use of the Affymetrix HG-
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U133A array containing more than 22,000 probe sets for
14,500 different genes. Approximately 10,000 genes were
found to be expressed in all the samples according to the
threshold of acceptance described in METHODS. The mRNAs
were categorized as tissue characteristic, but not necessarily
tissue/cell specific, by annotations from the NetAffx analysis
center. Figure 1A summarizes the overall number of muscle
(175) and hematopoietic tissue (169)-associated mRNAs, leav-
ing a large group of tissue-uncharacterized mRNAs or un-
known species. A total of 99 mRNAs were characteristic of
bone and extracellular matrix, as described previously (35).
Employing both criteria 1 and 2 for filtering and statis-
tical analysis (METHODS), 139 individual muscle- and 88
hematopoiesis-related mRNAs were detected. For patients
1– 6, a highly corresponding profile was found, in which the
majority of mRNAs were increased in muscle (Fig. 1B, a)
and decreased in hematopoietic tissue (Fig. 1B, b). Many of
the muscle and hematopoietic transcripts were more than
fourfold increased and 50% decreased, respectively, due to
PHPT (Fig. 1B, a and b).
Patient 7, however, showed a different mRNA expression
pattern of both hematopoiesis- and muscle-related genes com-
pared with patients 1–6 (see METHODS for detailed assessment)
and was therefore regarded as an outlier. The different data set
for patient 7 was not due to chip variations, as they are all from
the same batch as are also the kits used in the other processes,
nor was it due to differences in mRNA quality. Patient 7
probably represents a biological variant or possibly a different
disease stage; she was also much older than the other patients
(75 yr old compared with a mean age of 57.9 yr for the
remaining 6 patients).
Expression levels of PTHR1 and PTHR2 mRNAs in bone
biopsies from patients with PHPT and their distribution in
human tissues of unrelated persons. Real-time RT-PCR of
PTHR1 mRNA showed a 2.0  0.9-fold increase in PHPT,
whereas PTHR2 mRNA expression was unaltered, confirming
the Affymetrix data (35). The discovery of differential PTHR1
mRNA expression and the knowledge that PHPT precipitates
symptoms from various organs prompted us to study receptor
mRNA distribution in CNS, muscle, and blood cells. PTHR1
Fig. 1. A: overview of tissue-related genes
differentially expressed pre- and postop-
eratively in primary hyperparathyroidism
(PHPT) and fulfilling statistical criterion 1
or 2 for filtering. Most muscle tissue-related
mRNAs are increased with disease, in con-
trast to hematopoietic tissue mRNAs. B: in-
dividual expression of mRNAs characteristic
of muscle (119) (a) and hematopoietic cells
(88) (b) in each of 7 patients, representing the
most significantly regulated genes (1,388).
Each gene is displayed as a bar and expressed
as a ratio in log2 scale between pre- and post-
operative mRNA values for each individual
patient. Statistical criteria 1 and 2 for filtering
were fulfilled (see METHODS).
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and PTHR2 mRNAs were both present in all human tissues and
cells tested, except for the small intestine, where only PTHR1
mRNA was detected (Fig. 2). The abundant and uniform
representation of the two receptor mRNAs in the CNS, espe-
cially in the cerebellum, amygdala, hippocampus, superior
frontal gyrus, superior parietal gyrus, thalamus, and hypothal-
amus is noteworthy, reaching almost the level of actin (Fig. 2).
Cardiac and skeletal muscle contain, on average, about one-
tenth of the mRNA amounts present in the most enriched
regions of the brain. Thus, the prerequisite for PTH to exert a
direct action on muscle and hematopoietic tissue/cells is
present.
Differential expression of muscle- and hematopoiesis-related
mRNAs in PHPT. Functional groups of genes were identified
using annotations in the NetAffx analysis center and from Eli
Lilly as a second validation. The results were highly compa-
rable. The number of differentially displayed genes in each
functional category is presented in Fig. 3. Among muscle-
related transcripts there was an overrepresentation in the
groups “actin binding” and “protein binding.” Also, mRNAs
coding for ion binding and transport proteins were prominent.
Alterations in immune response and immune receptor genes
were the most striking features among the hematopoiesis-
related genes. The number of affected mRNAs for transcription
factors and transferases seemed to be similar in hematopoiesis
and muscle-characteristic genes (Fig. 3). The mRNAs defining
muscle proteins were related especially to energy processes
(e.g., creatine transferases) and to proteins participating in cellular
contractility and ion binding and transport (Figs. 3 and 4).
Individual changes in each patient describing 50 of the
statistically most affected genes in each functional category
characteristic of the two tissues are depicted in Fig. 4. By
compiling the data, reproducibility and consistency of the gene
expression results during disease in patients 1–6 were visual-
ized. During disease it was characteristic that mRNAs related
to the contractile and energy providing systems were most
Fig. 2. Expression levels of PTH receptors 1
and 2 (PTHR1 and PTHR2) mRNAs in var-
ious tissues relative to actin mRNA analyzed
by real-time RT-PCR. mRNA levels were
tested in triplicate from 3 different persons.
Bars illustrate means (SD).
Fig. 3. Functional classification of the most
significantly regulated genes between pre-
and postoperative values for mRNAs. For
statistical criteria, see Fig. 1.
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increased in muscle (Fig. 4A). Also, mRNAs for ion binding/
transport and transcription factors were highly regulated in the
patient biopsies before compared with after PTX. Some
muscle-related mRNAs were increased up to 10-fold (e.g.,
myozenin) during PHPT, whereas the majority were two- to
fourfold increased (Fig. 4A) (see http://www.med.uio.no/imb/
medbiokj/kgautvik/index.html for the genes affected in this
and the other affected canonical pathways). Of the 50 mus-
cle-related mRNAs depicted in Fig. 4A, only plakophilin-4
was reduced (almost 3-fold), whereas several other muscle-
related mRNAs also were significantly reduced in PHPT
(chondroitin sulfate, GalNAcT-2, ganglioside-induced differ-
entiation-associated protein-1, syntrophin, 1, glycerol-3-
phosphate dehydrogenase-2, calcitonin receptor-like; Fig. 1B,
a, but not shown in Fig. 4A). These do not represent members
of any obvious particular group or pathway, and their clinical
translation appears unclear.
During PHPT, some mRNAs related to hematopoietic func-
tions were increased, e.g., hepatic leukemia factor (HLF),
chemokines, and some mRNAs related to DNA binding and
transcription factors (Fig. 4B). The median degree of hemato-
poietic mRNA alteration (up/down) was 45%, whereas most
of the downregulated mRNAs were in fact reduced by 75%,
e.g., immunoglobulin heavy constant- (IGHG1; Fig. 4B). In
addition, receptor-signal transduction, certain chemokines,
e.g., IL-4, and transcription factors represented major mRNA
groups that were highly affected before and after curative
surgery.
To validate the findings of transcript measurements by the
microarray approach, we repeated the measurements of se-
lected mRNA levels using real-time RT-PCR on RNA from
patients 1, 2, 4, 5, and 6 (patient 3 was omitted due to limited
amounts of RNA). The results demonstrated a very good
consistency with the findings obtained using microchip analy-
sis and in general showed an even more pronounced change in
expression (Fig. 4).
The data have been submitted to the European Bioinformat-
ics Institute (EMBL-EBI) ArrayExpress repository (acc. no.
E-MEXP-847).
Identification of affected canonical pathways at PHPT and
clinical significance. A total of 1,388 genes that fulfilled statis-
tical criterion 1 or 2 (see Fig. 1A) (METHODS) were analyzed by
canonical IPA (Ingenuity Systems, www.ingenuity.com).
The canonical pathways present in the IPA library and
showing highest significance for our data set are displayed in
Table 1.
Several pathways that were not assigned to a predominant
tissue, but are of general biological importance, included en-
ergy metabolism represented by oxidative phosphorylation,
citrate cycle, pyruvate metabolism, pentose phosphate path-
way, and ubiquinone synthesis, all of which were strongly and
highly significantly affected during PHPT, showing an overall
increased expression pattern. It is of particular interest that the
“calcium-signaling” pathway, known to be essential in muscle
and blood cell functions, is by far the most affected system, in
which 50 of 172 mRNAs (30%) are altered. In agreement
with the profound alterations in the mRNA profiles of cell
receptors, cell signaling and chemokines as related to both
muscle and hematopoietic tissue/cells (Fig. 4) and the molec-
ular networks reflecting calcium and -adrenergic signal trans-
ductions were statistically most, and quite remarkably, pre-
dominantly increased during disease. Calcium plays essential
roles in skeletal and cardiac signal-contraction coupling but is
also of central importance for several hematological/immuno-
logical cellular functions. For instance, we find that several
mRNAs within the calcium-signaling pathway (CRAC, MEF2,
DSCR1, RyR) are affected in PHPT. Their corresponding
proteins participate in immune cell activation as well as in B
and T cell development via activation of the transcription
factor NFATC (the pathway and affected genes are illustrated
at http://www.med.uio.no/imb/medbiokj/kgautvik/canonical.html
and reviewed in Ref. 9). The 11 genes affected and present in
the -adrenergic signaling respond to the catecholamines nor-
epinephrine and epinephrine, providing coordinated control of
contractility, metabolism, and gene regulation, and can be
viewed at http://www.med.uio.no/imb/medbiokj/kgautvik/
canonical.html (reviewed in Ref. 37). It is well known that an
upset regulation of the -adrenergic system, which appears
also to be greatly overactivated in patients with PHPT, will
cause erroneous cardiac muscle cell function and, if of longer
duration, may lead to heart symptoms (reviewed in Ref. 25).
Other regulated pathways with long-term potential clinical
consequences are phenylalanine, tyrosine, and tryptophan bio-
synthesis and Parkinson’s signaling [a signaling cascade that in
brain leads to the death of dopaminergic neurons (reviewed in
Ref. 21)]. It is noteworthy that seven of nine enzyme com-
plexes in the oxidative phosphorylation chain were among the
most significantly altered, causing a potentially important im-
balance of muscle cell energy requirement (Table 1 and website
http://www.med.uio.no/imb/medbiokj/kgautvik/canonical.html).
DISCUSSION
The results show that patients with asymptomatic, mild
PHPT without known clinical organ involvement have a
marked, disease-dependent change in expression of mRNAs
characteristic of muscle- and hematopoiesis-related genes as
previously described for bone related genes (35). This dysregu-
lation of a large number of genes related to muscle and
hematopoiesis during PHPT has not previously been recog-
nized. Because the pathological biochemical parameters and
loss of bone mineral density were reversible after the opera-
tion, it is reasonable to attribute the molecular changes to being
caused by the disease. Also, changes in several bone-associated
mRNAs (e.g., osteopontin, osteocalcin, fibronectin-1, and sev-
eral collagens, including 1A1 and 1A2) previously shown to be
affected by PTH overstimulation (35) may be argued to rep-
resent a validation of the results even if the number of patients
is limited. All of the patients had high serum PTH while
showing small or modest rises in serum Ca2. Since the
median changes in serum PTH and Ca2 during disease were
5- and 1.25-fold, respectively, it is tempting to regard PTH, and
not serum Ca2, as a major cause of the molecular derange-
ment. In support of this view, it may be argued that, since the
local [Ca2] in bone marrow adjacent to trabeculi can be very
high irrespective of disease (40), a mere 25% increase in
[Ca2] would hardly have a significant effect on the hemato-
poietic stem cells that are closely associated with bone. Fur-
thermore, the fourth Tromsø Epidemiological Study, involving
nearly 7,000 persons, demonstrated a clear relationship be-
tween left ventricular hypertrophy and serum PTH with no
relation to serum calcium levels (36). As serum 1,25(OH)2D is
E1469ABNORMAL GENE EXPRESSION IN PHPT
AJP-Endocrinol Metab • VOL 292 • MAY 2007 • www.ajpendo.org






E1470 ABNORMAL GENE EXPRESSION IN PHPT
AJP-Endocrinol Metab • VOL 292 • MAY 2007 • www.ajpendo.org






also increased in PHPT (35), a contributing effect on gene
expression is possible due to increased activation of the vita-
min D3 receptors, since they are ubiquitously expressed (8, 12).
Vitamin D has antiproliferative effects on hematopoietic cells
mediated via induction of the cyclin-dependent kinase (CDK)
inhibitors p27kip1 and p21WAF1/CIP1 as well as via enhanced
TGF- signaling (reviewed in Refs. 28 and 44). The CDK
inhibitor p27kip1 mRNA is present but not changed, whereas
p21WAF1/CIP1 mRNA appears to be slightly increased. Al-
though mRNAs encoding the TGF-1 and SMAD’s mediating
TGF- signaling are not changed in PHPT, the TGF-RI and
TGF-RII mRNAs are slightly decreased [Array Express Re-
pository (E-MEXP-847)]. To what degree altered vitamin D
level is responsible for these small changes and what effects
they may have on expression of muscle- and hematopoiesis-
associated genes in PHPT is unclear. The presence of several
different cell types within the biopsies and tissues makes the
assignment and translation of molecular signals to cell function
difficult.
Except for bone and kidney, chronic receptor activation by
PTH in PHPT has not earlier been strongly linked to particular
clinical symptoms, possibly because CNS- and muscle-related
complaints have been difficult to assess objectively in medical
investigations. Morphological changes have been described in
cases where myopathy was part of the clinical picture in PHPT
(6), and it is notable that such changes have not been described
in other hypercalcemic conditions.
Recent knowledge indicates that several tissues express
many of the same type of genes. For example, isolated osteo-
cytes, which have been shown to be PTH dependent (30),
express many genes characteristic of muscles and CNS (18).
The present study therefore indicates that chronic PTH stimu-
lation affects defined groups of mRNAs expressed in all target
cells. It therefore became important to better define the human
target cells/tissues for PTH in order to understand the observed
molecular changes in relation to clinical cell and organ pathol-
ogy. Muscle function is heavily dependent on a continuous
energy supply, and the increased expression of genes related to
energy and metabolism will probably also lead to constant and
inappropriately elevated ATP generation when not linked to
muscular activity. Therefore, muscle cells in PHPT may de-
velop a state of energy insufficiency’s being relevant in ex-
plaining muscular atrophy, weakness, and fatigue, which are
commonly reported by patients with this disease (29). The
canonical pathway most significantly affected was calcium
signaling, in which 50 of 172 mRNAs showed changed ex-
pression during disease. Most of these mRNAs encode proteins
participating in the typical muscle contractile process (myo-
sins, troponins, tropomyosins, Ca2-binding proteins, and
Ca2 channel proteins). It is also a striking feature of the
discovered molecular pathology that it probably also involves
the cardiac -adrenergic system present in cardiomyocytes.
This finding may help explain the dysregulation of cardiac
function and development of left ventricular hypertrophy and
failure representing the main cause of premature death in
patients with PHPT (20, 36).
Also, expression of genes that regulate proliferation and
differentiation of muscle-related cells was altered in patients
with PHPT: MyoD1, which induces the transcription factors
myogenin (increased in PHPT) and MRF4 (reviewed in Ref.
5), and calpain 3. The latter is a protease participating in
sarcomere remodeling by cleaving filamin C involved in myo-
cyte differentiation (50). A possible correlation between the
degree of clinical severity of muscle and CNS affection, and
extent of molecular derangement, must await further studies,
since the present patients had early disease and did not present
typical clinical morbidity or biochemical blood changes; e.g.,
serum creatinine levels were normal (data not shown).
The association between PHPT and immunological dysfunc-
tion is not recognized today but may be of clinical importance.
Reduced resistance to infections and increased prevalence and
premature death of malignant diseases in PHPT have been
reported (1, 3, 11, 13, 20, 32). A relationship between PHPT
and infection is described as being the fourth most prevalent
cause of premature death (20). Also, the high prevalence of
Helicobacter pylori in patients with PHPT (11) and urinary
tract infections in 26% of 201 tested dogs with PHPT (13)
points to an increased susceptibility to infections. Of the 55
different genes described by Affymetrix to affect the innate
immune system, three showed significantly reduced expression
in PHPT [complement component 7, complement component
(3b/4b) receptor 1, and toll-like receptor-1], whereas one (clus-
terin) was increased. In our patients with PHPT, a number of
chemokine mRNAs were altered and, e.g., IL-4 mRNA was
increased 2.6-fold (log2 	 1.37; Fig. 4B). It is of interest that
Fig. 4. Cumulative changes of regulated known mRNAs shown as pre- and postoperative ratios and grouped into functional categories. In both panels, a selection
of the 5 most regulated mRNAs in 10 different groups is displayed. Each bar shows the compiled change in 1 gene for each patient. Results from real-time
RT-PCR are shown as an adjacent bar. Means (SD) of patients 1, 2, 4, 5, and 6 are listed for real-time RT-PCR results, while patient 3 is also included in results
from microchip analysis. A: muscle. B: hematopoietic cells. Genes labeled with an asterisk fulfill criterion 1 or 2 for filtering and statistical analysis on
parathyroidectomy (PTX), whereas those not marked fulfill both criteria. Tables with all muscle- and hematopoiesis-regulated mRNAs are displayed at
http://www.med.uio.no/imb/medbiokj/kgautvik/canonical.html.









Calsium signaling 50/112 46/4 0.000
Cardiac -adrenergic
signaling 19/77 13/6 0.000
Oxidative phosphorylation 28/143 27/1 0.001
Citrate cycle 8/27 7/1 0.007
Phenylalanine, tyrosine, and
tryptophan biosynthesis 5/14 3/2 0.012
Pyruvate metabolism 14/70 12/2 0.016
Pentose phosphate pathway 8/33 5/3 0.028
Parkinson’s signaling 5/17 2/3 0.029
Ubiquinone biosynthesis 10/49 10/ 0.036
Pathways within the Ingenuity Pathways Knowledge Base that were most
significantly regulated among the 1,388 genes fulfilling statistical criterion 1 or
2 (see METHODS). PHPT, primary hyperparathyroidism. Significance of the
association between the data set and the canonical pathway were analyzed in
2 ways: 1) ratio of no. of genes from the data set that map to the pathway
divided by the total no. of genes that map to the canonical; 2) Fischer’s exact
test, used to calculate a P value testing the hypothesis that the association
between the genes in the dataset and the canonical pathway is explained by
chance alone.
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production of IL-6, sIL-6R, and TNF-
 from cultured white
blood cells is elevated in patients with PHPT before operation,
showing a PTH-dependent biochemical abnormality in a he-
matological cell lineage (15–17, 34) (IL-4 was not analyzed in
blood). These molecular and biochemical pathways point to a
possible clinical relationship. In this respect, it is of interest that
PTH-(1–34) treatment of mice caused expansion of hematopoietic
stem cell precursors (4). Furthermore, we find mRNAs for im-
munoglobulins, immunoglobulin receptors, signal transduction
mediators, and growth factors to be altered in PHPT. A
possible reduced response to antigens may contribute to the
increased susceptibility to cancer and infections.
Mesenchymal cells in the bone marrow are the source of
osteogenic cell differentiation and osteoblastic cells, which
together with immune cell precursors constitute the hemato-
poietic stem cell niche (4). The Wnt pathway is central in both
osteoblast and hematopoietic differentiation and proliferation.
Interestingly, several genes involved in Wnt signaling show
significantly higher expression in PHPT [Wnt5A, Wnt3, friz-
zled 7, dishevelled 1, LRP16, and Dickkopf (Dkk) 2; Array
Express Repository (E-MEXP-847)], suggesting a role for
some of these factors in contributing to the pathological picture
in PHPT. mRNAs encoding downstream mediators of the Wnt
pathway (-catenin, GSK-3, LEF-1/T cell factor) were not
significantly altered or were undetectable on the chip.
Because PTHR1, but not the PTHR2, was found to be
significantly (2-fold) increased in disease, thereby providing a
molecular basis for PTH target cell dysregulation, we exam-
ined in some detail their distribution in human CNS, muscle,
and blood cells. By real-time RT-PCR analysis we showed the
presence of both PTHR1 and PTHR2 mRNAs in human
monocytes, lymphocytes, bone marrow, and heart muscle, and
both receptor mRNAs were markedly expressed in several
regions of the brain. These results, which add to and extend
previous knowledge (39), offer a molecular understanding to
explain the CNS and muscle pathophysiology in PHPT.
In gene-modulated mice, bone-specific expression of consti-
tutively active PTHR1 led to perturbed hematopoiesis and a
greatly reduced number of clonogenic stromal cells (27). Fur-
thermore, other animal studies have shown that osteopontin
reduces the hematopoietic stem cell pool (45). In PHPT we
have observed activation of PTH1R as well as increased
osteopontin mRNA levels, as shown previously (35). Thus, one
interesting hypothesis warranting further research is that the
number of hematopoietic stem cells may be reduced in PHPT
as a consequence of chronic PTH stimulation, an effect oppo-
site to the action of brief PTH infusion (4). The profound
changes observed in specific molecular patterns analyzed by
global gene expression as demonstrated in our study suggest a
number of mechanisms that may translate to and well explain
recognized clinical consequences of PHPT, providing strong
directions for further research. The present results indicate that
early diagnosis and treatment of these patients may avoid
irreversible molecular pathology.
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